May 25, 2015November 9, 2015

Novartis Reveals Promising Results on Phase III Trials for Two Therapeutic Drugs against COPD

COPD, News

Novartis recently announced encouraging positive results on two of its pivotal Phase III clinical trial programs, the EXPEDITION program to assess the efficacy of QVA149 (indacaterol/glycopyrronium bromide) and the GEM program ... Read more

January 9, 2015November 11, 2015

Novartis Reveals Two COPD Drugs’ Positive Phase III Results and NDA Submission

COPD, News

Novartis recently announced robust findings from a pivotal Phase III clinical study for QVA149 (indacaterol/glycopyrronium bromide) and NVA237 (glycopyrronium bromide), meant to support these pipeline medications’ New Drug Applications with the ... Read more